Workshop 5: Assessment of efficacy

William W. Busse, Archie F. Wilson, Saul S. Bodenheimer, Ronald D. Fairshter, Richard F. Lockey, Harold S. Nelson, Philip S. Norman, Robert E. Reisman, Patricia H. Russell, David L. Winter

Research output: Contribution to journalArticle

Abstract

The efficacy of NBAAD can be assessed by periodic timed evaluation with precise spirometry and daily peak flow determinations and by measuring effect on airway hyperresponsiveness before, during, and after the drug trial. In addition, close monitoring and careful analyses of symptoms and use of concomitant medications are important efficacy parameters. Under certain conditions eosinophils in blood and sputum may provide useful objective criteria of efficacy. Demonstration of improvement in asthma with NBAAD should be based on a collective assessment of airway function, daily symptoms, and use of concomitant medications.

Original languageEnglish (US)
Pages (from-to)525-528
Number of pages4
JournalThe Journal of Allergy and Clinical Immunology
Volume78
Issue number3 PART 2
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Spirometry
Sputum
Eosinophils
Asthma
Education
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Busse, W. W., Wilson, A. F., Bodenheimer, S. S., Fairshter, R. D., Lockey, R. F., Nelson, H. S., ... Winter, D. L. (1986). Workshop 5: Assessment of efficacy. The Journal of Allergy and Clinical Immunology, 78(3 PART 2), 525-528. https://doi.org/10.1016/0091-6749(86)90099-0

Workshop 5 : Assessment of efficacy. / Busse, William W.; Wilson, Archie F.; Bodenheimer, Saul S.; Fairshter, Ronald D.; Lockey, Richard F.; Nelson, Harold S.; Norman, Philip S.; Reisman, Robert E.; Russell, Patricia H.; Winter, David L.

In: The Journal of Allergy and Clinical Immunology, Vol. 78, No. 3 PART 2, 1986, p. 525-528.

Research output: Contribution to journalArticle

Busse, WW, Wilson, AF, Bodenheimer, SS, Fairshter, RD, Lockey, RF, Nelson, HS, Norman, PS, Reisman, RE, Russell, PH & Winter, DL 1986, 'Workshop 5: Assessment of efficacy', The Journal of Allergy and Clinical Immunology, vol. 78, no. 3 PART 2, pp. 525-528. https://doi.org/10.1016/0091-6749(86)90099-0
Busse WW, Wilson AF, Bodenheimer SS, Fairshter RD, Lockey RF, Nelson HS et al. Workshop 5: Assessment of efficacy. The Journal of Allergy and Clinical Immunology. 1986;78(3 PART 2):525-528. https://doi.org/10.1016/0091-6749(86)90099-0
Busse, William W. ; Wilson, Archie F. ; Bodenheimer, Saul S. ; Fairshter, Ronald D. ; Lockey, Richard F. ; Nelson, Harold S. ; Norman, Philip S. ; Reisman, Robert E. ; Russell, Patricia H. ; Winter, David L. / Workshop 5 : Assessment of efficacy. In: The Journal of Allergy and Clinical Immunology. 1986 ; Vol. 78, No. 3 PART 2. pp. 525-528.
@article{eb65ec2b834541599b3f8333d591edc9,
title = "Workshop 5: Assessment of efficacy",
abstract = "The efficacy of NBAAD can be assessed by periodic timed evaluation with precise spirometry and daily peak flow determinations and by measuring effect on airway hyperresponsiveness before, during, and after the drug trial. In addition, close monitoring and careful analyses of symptoms and use of concomitant medications are important efficacy parameters. Under certain conditions eosinophils in blood and sputum may provide useful objective criteria of efficacy. Demonstration of improvement in asthma with NBAAD should be based on a collective assessment of airway function, daily symptoms, and use of concomitant medications.",
author = "Busse, {William W.} and Wilson, {Archie F.} and Bodenheimer, {Saul S.} and Fairshter, {Ronald D.} and Lockey, {Richard F.} and Nelson, {Harold S.} and Norman, {Philip S.} and Reisman, {Robert E.} and Russell, {Patricia H.} and Winter, {David L.}",
year = "1986",
doi = "10.1016/0091-6749(86)90099-0",
language = "English (US)",
volume = "78",
pages = "525--528",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3 PART 2",

}

TY - JOUR

T1 - Workshop 5

T2 - Assessment of efficacy

AU - Busse, William W.

AU - Wilson, Archie F.

AU - Bodenheimer, Saul S.

AU - Fairshter, Ronald D.

AU - Lockey, Richard F.

AU - Nelson, Harold S.

AU - Norman, Philip S.

AU - Reisman, Robert E.

AU - Russell, Patricia H.

AU - Winter, David L.

PY - 1986

Y1 - 1986

N2 - The efficacy of NBAAD can be assessed by periodic timed evaluation with precise spirometry and daily peak flow determinations and by measuring effect on airway hyperresponsiveness before, during, and after the drug trial. In addition, close monitoring and careful analyses of symptoms and use of concomitant medications are important efficacy parameters. Under certain conditions eosinophils in blood and sputum may provide useful objective criteria of efficacy. Demonstration of improvement in asthma with NBAAD should be based on a collective assessment of airway function, daily symptoms, and use of concomitant medications.

AB - The efficacy of NBAAD can be assessed by periodic timed evaluation with precise spirometry and daily peak flow determinations and by measuring effect on airway hyperresponsiveness before, during, and after the drug trial. In addition, close monitoring and careful analyses of symptoms and use of concomitant medications are important efficacy parameters. Under certain conditions eosinophils in blood and sputum may provide useful objective criteria of efficacy. Demonstration of improvement in asthma with NBAAD should be based on a collective assessment of airway function, daily symptoms, and use of concomitant medications.

UR - http://www.scopus.com/inward/record.url?scp=0022553293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022553293&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(86)90099-0

DO - 10.1016/0091-6749(86)90099-0

M3 - Article

AN - SCOPUS:0022553293

VL - 78

SP - 525

EP - 528

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3 PART 2

ER -